Author information
1 Senior Data Analyst, Viral Hepatitis Program, Bureau of Communicable Disease, Division of Disease Control, Department of Health and Mental Hygiene, New York City, Queens, NY, USA.
2 Director, Data Analysis Unit, Reportable Disease Data, Informatics, and Analysis Unit, Bureau of Communicable Disease, Division of Disease Control, Department of Health and Mental Hygiene, New York City, Queens, NY, USA.
3 Director of Viral Hepatitis Surveillance, Viral Hepatitis Program, Bureau of Communicable Disease, Division of Disease Control, Department of Health and Mental Hygiene, New York City, Queens, NY, USA.
4 State Epidemiologist, Massachusetts Department of Public Health, Boston, MA, USA.
5 HAI, TB, and Viral Hepatitis Section Manager, Communicable Disease Division, Michigan Department of Health and Human Services, Body Art Licensure, Lansing, MI, USA.
6 Viral Hepatitis Epidemiologist, Division of Disease Control, Department of Public Health, Philadelphia, PA, USA.
7 Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, MA, USA.
8 Surveillance and Informatics Epidemiologist, Office of Health Protection, Division of Infectious Disease, Illinois Department of Public Health, Chicago, IL, USA.
9 Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, Division of Disease Control, Department of Health and Mental Hygiene, New York City, Queens, NY, USA.
Abstract
Millions of persons in the United States are infected with hepatitis C virus (HCV).1 Medications that can cure chronic HCV infection in the vast majority of persons with minimal side effects and in a short duration have been available since 2013 and offer the prospect that HCV can be eliminated.2 An important metric necessary for elimination is knowing HCV prevalence at more granular levels than just nationally.